Recent research is casting a spotlight on Natural Killer (NK) cells and their potential role in the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. These cells, integral to the innate immune system, are known for their ability to detect and respond to infected, stressed, or abnormal cells. They also engage with other immune cells, influencing inflammatory responses through the release of signaling molecules. However, despite growing interest, clinical evidence supporting NK cell therapy as a treatment for these conditions is still in the early stages.
In the pursuit of understanding the connection between immune activity and neurodegeneration, scientists have been investigating how NK cells might impact disease processes in the brain. This is particularly relevant for diseases like Alzheimer’s and Parkinson’s, which involve complex mechanisms such as chronic inflammation and abnormal protein accumulation. A Phase I clinical study in 2025 explored the safety of expanded NK cells in 11 Alzheimer’s patients, focusing on cognitive measures and cerebrospinal fluid biomarkers linked to neuroinflammation and neurodegeneration. Although the study noted no adverse effects related to the NK cell product and some changes in cognitive measures and biomarkers, the small sample size means that conclusions about the therapy’s effectiveness cannot yet be drawn.
Interest in NK cells extends to Parkinson’s disease as well. A 2020 study published in the Proceedings of the National Academy of Sciences highlighted how NK cells interact with and degrade alpha-synuclein aggregates in lab and animal models. This research also indicated that when NK cells were depleted in a mouse model, there was an increase in alpha-synuclein pathology and neuroinflammation. These preclinical findings suggest a role for NK cells in managing Parkinson’s disease-related immune activity, but they do not confirm that NK cell therapy can treat the disease in humans.
The ongoing research into NK cells is revealing the complexity of their functions in neurological diseases. Different NK cell populations can have varied effects depending on the disease type, stage, and tissue environment, which means simply increasing NK cell numbers might not yield positive outcomes. Scientists are examining which NK cell populations, activation states, doses, and treatment schedules could be beneficial. Critical questions remain about the effectiveness of NK cells in influencing the central nervous system, the duration of their activity, the patient populations that might benefit, and whether such treatments can alter long-term disease progression.
While NK cells are recognized for their role in immune surveillance and regulation, the evidence connecting them to neuroinflammation and abnormal protein aggregates, particularly alpha-synuclein, is still emerging. At this stage, NK cell therapy is an investigational area of cellular medicine, requiring further clinical studies to confirm its efficacy and safety. Individuals considering such therapies should consult healthcare professionals to assess available scientific evidence and regulatory status. This article serves an educational purpose and does not offer medical advice or treatment options for neurodegenerative diseases.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.